**Patient Discharge Summary**

**Patient Information:**

* Name: Jane Doe
* Date of Birth: March 12, 1990
* Sex: Female
* Admitting Diagnosis: Type 1 Diabetes Mellitus

**Hospital Stay:**

* Admitted to the Endocrinology Unit on February 10, 2023, with a Chief Complaint of polyuria, polydipsia, and fatigue.
* Initial evaluation revealed a fasting plasma glucose (FPG) level of 350 mg/dL (19.4 mmol/L) and a glycosylated hemoglobin (HbA1C) level of 12.1%.
* Oral glucose tolerance testing (OGTT) was performed on February 12, 2023, with a peak glucose level of 450 mg/dL (25.0 mmol/L) at 2 hours.
* The patient was diagnosed with type 1 diabetes mellitus based on the American Diabetes Association (ADA) diagnostic criteria.

**Treatment:**

* Initiated insulin therapy with a basal-bolus regimen using insulin glargine (Lantus) 10 units subcutaneously at bedtime and insulin aspart (NovoLog) 10 units subcutaneously before meals.
* Dose adjustments were made as needed based on self-monitored blood glucose (SMBG) levels and hemoglobin A1c (HbA1c) measurements.
* Initial insulin doses were titrated to achieve a target fasting blood glucose level of 80-130 mg/dL (4.4-7.2 mmol/L) and postprandial blood glucose levels of < 180 mg/dL (10.0 mmol/L).

**Medications:**

* Insulin glargine (Lantus) 10 units subcutaneously at bedtime
* Insulin aspart (NovoLog) 10 units subcutaneously before meals
* Metformin (Glucophage) 500 mg orally twice daily (initiated on February 15, 2023, as a second-line agent)

**Patient Education:**

* Educated on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications.
* Provided information on diet, exercise, medication, and monitoring.
* Encouraged to perform SMBG at least 4 times daily and to adjust insulin doses based on results.
* Discussed the importance of regular professional podiatric care and vaccination against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2.

**Follow-up:**

* Scheduled follow-up appointment with the Endocrinology Clinic on March 15, 2023, for HbA1c measurement and insulin dose adjustment.
* Encouraged to continue SMBG and to report any changes in symptoms or blood glucose levels.

**Discharge Instructions:**

* Continue insulin therapy as prescribed.
* Perform SMBG at least 4 times daily.
* Adjust insulin doses based on SMBG results.
* Monitor for signs and symptoms of hypoglycemia and hyperglycemia.
* Attend scheduled follow-up appointments with the Endocrinology Clinic.
* Report any changes in symptoms or blood glucose levels to the healthcare provider.

**Additional Recommendations:**

* Consider GLP-1 receptor agonist therapy as a second-line agent based on HbA1c levels and blood glucose control.
* Monitor for signs of peripheral neuropathy and perform annual foot examinations.
* Schedule annual or biennial funduscopic examinations by an ophthalmologist.

**Signature:**

Dr. Jane Smith, MD
Endocrinology Unit
[Date]

Note: This discharge summary is a sample and may need to be tailored to the specific patient and their medical history.